公开(公告)号：US20220127649A1

公开(公告)日：2022-04-28

申请号：US17427019

申请日：2020-01-30

Applicant: Genomatica, Inc.

Inventor： Michael A. Noble ,  Jonathan Moore ,  Jingyi Li ,  Anna Lechner

IPC: C12P7/42 ,  C12N1/20 ,  C12N15/52 ,  C12N15/70 ,  C12P7/22

Abstract: The invention provides non-natural microbial organisms containing enzymatic pathways and/or metabolic modifications for enhancing synthesis of olivetolic acid, olivetolic acid derivatives and/or cannabinoids.

公开(公告)号：US20220347192A1

公开(公告)日：2022-11-03

申请号：US17640196

申请日：2020-09-04

Applicant: Genomatica, Inc.

Inventor： Michael A. Noble ,  Kevin G. Hoff ,  Russell S. Komor

IPC: A61K31/60 ,  C12N1/20 ,  C12N15/52 ,  C12P7/42 ,  C12P17/06 ,  A61K31/05 ,  A61K31/352 ,  A61K35/742 ,  A61K35/74 ,  A61K36/062 ,  A61K36/02

Abstract: Described herein are non-natural variants of prenyltronsfcrases having at least one amino acid substitution as compared to its corresponding natural or unmodified prenyltransferascs. The variants are capable of an increased rate of formation of prenylated aromatic compounds, such as cannabinoids, as compared to a wild type control The prcnyltransferase variants can be expressed in an engineered microbe having a pathway to such cannabinoids, and optionally can include one or more other pathway transgencs to promote formation of substrate(s) for the prcnyltransferases. Therapeutically useful cannabinoids can be purified from engineered cells and cell cultures.

公开(公告)号：US20240052332A1

公开(公告)日：2024-02-15

申请号：US18266238

申请日：2021-12-08

Applicant: Genomatica, Inc.

Inventor： Michael A. Noble ,  Sarah Skye McNees ,  Darlene Jan Abcede Usi ,  Joseph R. Warner

IPC: C12N9/88 ,  C12P7/42

CPC classification number: C12N9/88 ,  C12Y404/01026 ,  C12P7/42

Abstract: Described herein are non-natural olivetolic acid cyclases (OAC) variants capable of forming a 2,4-dihydroxy-6-alkylbenzoic acid from a 3,5,7-trioxoacyl-CoA or a 3,5,7-trioxocarboxylate substrate at a greater rate than a wild type or control OAC. The non-natural OAC (and OLS) can be expressed in an engineered cell having a pathway to form cannabinoids, which include CBGA, its analogs and derivatives. CBGA can be used for the preparation of cannabigerol (CBG), which can be used in therapeutic compositions.

公开(公告)号：US20220177858A1

公开(公告)日：2022-06-09

申请号：US17604722

申请日：2020-04-17

Applicant: Genomatica, Inc.

Inventor： Michael A. Noble ,  Russell Scott Komor ,  Jingyi Li

IPC: C12N9/10 ,  C12N15/52 ,  C12N1/20 ,  C12P7/22

Abstract: Described herein are non-natural olivetol synthase (OLS) variants, nucleic acids, engineered cells, method s for preparing cannabinoids, and compositions thereof. The non-natural olivetol OLS variants form desired cannabinoid precursor and products at increased rates, have higher affinity for pathway substrates, and/or byproducts are formed in lower amounts in their presence, as compared to wild type OLS. The OLS variants can be used to form linear polyketides, and can be expressed in an engineered cell having a pathway to form cannabinoids, which include CBGA, its analogs and derivatives. CBGA can be used for the preparation of cannabigerol (CBG), which can be used in therapeutic compositions.

公开(公告)号：US20230374473A1

公开(公告)日：2023-11-23

申请号：US18316993

申请日：2023-05-12

Applicant: Genomatica, Inc.

Inventor： Michael A. Noble ,  Kevin G. Hoff ,  Anna Lechner ,  Harish Nagarajan

IPC: C12N9/10 ,  C12P7/22 ,  C12P7/42

CPC classification number: C12N9/1085 ,  C12P7/22 ,  C12P7/42

Abstract: Described herein are prenyltransferases including non-natural variants thereof having at least one amino acid substitution as compared to its corresponding natural or unmodified prenyltransferases and that are capable of at least two-fold greater rate of formation of cannabinoids such as cannabigerolic acid, cannabigerovarinic acid, cannabigerorcinic acid, and cannabigerol, as compared to a wild type control. Prenyltransferase variants also demonstrated regioselectivity to desired cannabinoid isomers such as CDBA (3-GOLA), 3-GDVA, 3-GOSA, and CBG (2-GOL). The prenyltransferase variants can be used to form prenylated aromatic compounds, and can be expressed in an engineered microbe having a pathway to such compounds, which include 3-GOLA, 3-GDVA, 3-GOSA, and CBG. 3-GOLA can be used for the preparation of cannabigerol (CBG), which can be used in therapeutic compositions.

公开(公告)号：US11685908B2

公开(公告)日：2023-06-27

申请号：US16978629

申请日：2019-03-08

Applicant: Genomatica, Inc.

Inventor： Michael A. Noble ,  Kevin G. Hoff ,  Anna Lechner ,  Harish Nagarajan

IPC: C12N9/10 ,  C12P7/22 ,  C12P7/42

CPC classification number: C12N9/1085 ,  C12P7/22 ,  C12P7/42

Abstract: Described herein are prenyltransferases including non-natural variants thereof having at least one amino acid substitution as compared to its corresponding natural or unmodified prenyltransferases and that are capable of at least two-fold greater rate of formation of cannabinoids such as cannabigerolic acid, cannabigerovarinic acid, cannabigerorcinic acid, and cannabigerol, as compared to a wild type control. Prenyltransferase variants also demonstrated regioselectivity to desired cannabinoid isomers such as CDBA (3-GOLA), 3-GDVA, 3-GOSA, and CBG (2-GOL). The prenyltransferase variants can be used to form prenylated aromatic compounds, and can be expressed in an engineered microbe having a pathway to such compounds, which include 3-GOLA, 3-GDVA, 3-GOSA, and CBG. 3-GOLA can be used for the preparation of cannabigerol (CBG), which can be used in therapeutic compositions.

公开(公告)号：US20210254030A1

公开(公告)日：2021-08-19

申请号：US16978629

申请日：2019-03-08

Applicant: Genomatica, Inc.

Inventor： Michael A. Noble ,  Kevin G. Hoff ,  Anna Lechner ,  Harish Nagarajan

IPC: C12N9/10 ,  C12P7/42 ,  C12P7/22

Abstract: Described herein are prenyltransferases including non-natural variants thereof having at least one amino acid substitution as compared to its corresponding natural or unmodified prenyltransferases and that are capable of at least two-fold greater rate of formation of cannabinoids such as cannabigerolic acid, cannabigerovarinic acid, cannabigerorcinic acid, and cannabigerol, as compared to a wild type control. Prenyltransferase variants also demonstrated regioselectivity to desired cannabinoid isomers such as CDBA (3-GOLA), 3-GDVA, 3-GOSA, and CBG (2-GOL). The prenyltransferase variants can be used to form prenylated aromatic compounds, and can be expressed in an engineered microbe having a pathway to such compounds, which include 3-GOLA, 3-GDVA, 3-GOSA, and CBG. 3-GOLA can be used for the preparation of cannabigerol (CBG), which can be used in therapeutic compositions.